$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

$arwr Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000162828024003492 Filed on February 06, 2024

Income Statement

Concept	2024 Q1	2023 Q4
Revenue	$0.00	$3.551M
YoY Change	-100.0%	-94.32%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$28.05M	$26.19M
YoY Change	11.5%	15.61%
% of Gross Profit
Research & Development	$101.1M	$116.5M
YoY Change	35.04%	39.19%
% of Gross Profit
Depreciation & Amortization	$4.100M	$3.800M
YoY Change	86.36%	65.22%
% of Gross Profit
Operating Expenses	$126.2M	$140.1M
YoY Change	28.63%	33.83%
Operating Profit	-$126.2M	-$136.5M
YoY Change	-362.0%	224.07%
Interest Expense	$7.244M	$5.367M
YoY Change	43.25%	-3313.77%
% of Operating Profit
Other Income/Expense, Net	-$805.0K	-$2.144M
YoY Change	64.62%	-730.59%
Pretax Income	-$127.0M	-$138.7M
YoY Change	-366.37%	231.84%
Income Tax	$0.00	-$3.300M
% Of Pretax Income
Net Earnings	-$125.3M	-$132.9M
YoY Change	-357.42%	221.51%
Net Earnings / Revenue		-3741.59%
Basic Earnings Per Share	-$1.02	-$1.24
Diluted Earnings Per Share	-$1.02	-$1.24
COMMON SHARES
Basic Shares Outstanding	123.9M shares	107.4M shares
Diluted Shares Outstanding	123.3M shares	107.4M shares

Balance Sheet

Concept	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$523.1M	$220.3M
YoY Change	8.75%	-56.11%
Cash & Equivalents	$127.7M	$58.20M
Short-Term Investments	$395.4M	$162.1M
Other Short-Term Assets	$7.514M	$7.104M
YoY Change	-47.95%	-71.8%
Inventory
Prepaid Expenses	$11.02M	$10.52M
Receivables
Other Receivables
Total Short-Term Assets	$541.7M	$237.9M
YoY Change	-5.77%	-58.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$359.3M	$333.4M
YoY Change	93.95%	126.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$210.0K	$232.0K
YoY Change	0.0%	10.48%
Total Long-Term Assets	$413.5M	$388.4M
YoY Change	30.65%	22.72%
TOTAL ASSETS
Total Short-Term Assets	$541.7M	$237.9M
Total Long-Term Assets	$413.5M	$388.4M
Total Assets	$955.2M	$626.3M
YoY Change	7.16%	-29.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.521M	$4.460M
YoY Change	-10.83%	460.3%
Accrued Expenses	$37.06M	$46.60M
YoY Change	-6.31%	-3.26%
Deferred Revenue	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$65.18M	$63.72M
YoY Change	-25.22%	-47.77%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$394.6M	$388.8M
YoY Change	16.37%	4.22%
Total Long-Term Liabilities	$394.6M	$388.8M
YoY Change	16.37%	4.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$65.18M	$63.72M
Total Long-Term Liabilities	$394.6M	$388.8M
Total Liabilities	$459.7M	$452.6M
YoY Change	7.87%	-8.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.284B	-$1.159B
YoY Change	57.88%	34.43%
Common Stock	$1.769B	$1.321B
YoY Change	40.35%	6.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$483.8M	$160.4M
YoY Change
Total Liabilities & Shareholders Equity	$955.2M	$626.3M
YoY Change	7.16%	-29.75%

Cashflow Statement

Concept	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$125.3M	-$132.9M
YoY Change	-357.42%	221.51%
Depreciation, Depletion And Amortization	$4.100M	$3.800M
YoY Change	86.36%	65.22%
Cash From Operating Activities	-$92.38M	-$117.8M
YoY Change	191.68%	56.05%
INVESTING ACTIVITIES
Capital Expenditures	$34.07M	$68.66M
YoY Change	24.75%	76.44%
Acquisitions
YoY Change
Other Investing Activities	-$234.9M	$133.5M
YoY Change	2583.83%	-419.5%
Cash From Investing Activities	-$268.9M	$64.84M
YoY Change	645.7%	-180.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	430.8M	$267.0K
YoY Change	82741.73%	-99.89%
NET CHANGE
Cash From Operating Activities	-92.38M	-$117.8M
Cash From Investing Activities	-268.9M	$64.84M
Cash From Financing Activities	430.8M	$267.0K
Net Change In Cash	69.46M	-$52.73M
YoY Change	-203.34%	-155.88%
FREE CASH FLOW
Cash From Operating Activities	-$92.38M	-$117.8M
Capital Expenditures	$34.07M	$68.66M
Free Cash Flow	-$126.5M	-$186.5M
YoY Change	114.38%	62.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	116491000	usd
CY2022Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	83695000	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23605000	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20985000	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	140096000	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	104680000	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-136545000	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-42134000	usd
CY2023Q4	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	2802000	usd
CY2022Q4	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	2682000	usd
CY2023Q4	us-gaap	Interest Expense InterestExpense	5367000	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	2849000	usd
CY2023Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	421000	usd
CY2022Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	507000	usd
CY2023Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2144000	usd
CY2022Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	340000	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-138689000	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-41794000	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3313000	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-135376000	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-41811000	usd
CY2023Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2512000	usd
CY2022Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-486000	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-132864000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-41325000	usd
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.24
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.24
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107415000	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106039000	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107415000	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106039000	shares
CY2023Q4	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1909000	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2023Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	58000	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-122000	usd
CY2023Q4	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-133409000	usd
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-41933000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	287162000	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19694000	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	267000	usd
CY2023Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	58000	usd
CY2023Q4	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1909000	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-135376000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	173714000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	418339000	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19390000	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	576000	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-122000	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-41811000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	396372000	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-135376000	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-41811000	usd
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	19694000	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	19390000	usd
CY2023Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4263000	usd
CY2022Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2689000	usd
CY2023Q4	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	835000	usd
CY2022Q4	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-690000	usd
CY2023Q4	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	80000	usd
CY2022Q4	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2023Q4	arwr	Non Cash Interest Expense Liability Related To Sale Of Future Royalties NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	5367000	usd
CY2022Q4	arwr	Non Cash Interest Expense Liability Related To Sale Of Future Royalties NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	2849000	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	38157000	usd
CY2023Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1748000	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-10529000	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-12463000	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2072000	usd
CY2023Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	408000	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-7203000	usd
CY2023Q4	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-866000	usd
CY2022Q4	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-22979000	usd
CY2023Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	3796000	usd
CY2022Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	559000	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-117840000	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-75516000	usd
CY2023Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	68656000	usd
CY2022Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	38911000	usd
CY2023Q4	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	usd
CY2022Q4	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	111199000	usd
CY2023Q4	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	133495000	usd
CY2022Q4	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	69416000	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	64839000	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-80694000	usd
CY2023Q4	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	267000	usd
CY2022Q4	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	576000	usd
CY2023Q4	arwr	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	0	usd
CY2022Q4	arwr	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	250000000	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	267000	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	250576000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-52734000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	94366000	usd
CY2023Q4	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58000	usd
CY2022Q4	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-122000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110891000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108005000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58215000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	202249000	usd
CY2023Q4	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022Q4	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023Q4	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-999000	usd
CY2022Q4	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q4	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	11290000	usd
CY2022Q4	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	14044000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58200000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	6900000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	162100000	usd
CY2023Q4	arwr	Increase Decrease In Cash And Investments IncreaseDecreaseInCashAndInvestments	-183300000	usd
CY2023Q4	arwr	Development Regulatory And Sales Milestones Payments DevelopmentRegulatoryAndSalesMilestonesPayments	2800000000	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3300000	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3551000	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	62546000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	866000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	295699000	usd
CY2023Q3	arwr	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent	0	usd
CY2023Q3	arwr	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent	2964000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	292735000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	379200000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	332213000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45789000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41951000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	333411000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	290262000	usd
CY2023Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3800000	usd
CY2022Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2300000	usd
CY2023Q4	arwr	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	18106000	usd
CY2023Q3	arwr	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	16125000	usd
CY2023Q4	arwr	Accrued Research And Development Co Development Expense Current AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent	11104000	usd
CY2023Q3	arwr	Accrued Research And Development Co Development Expense Current AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent	5895000	usd
CY2023Q4	arwr	Accrued Capital Expenditure Current AccruedCapitalExpenditureCurrent	11290000	usd
CY2023Q3	arwr	Accrued Capital Expenditure Current AccruedCapitalExpenditureCurrent	14044000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6104000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3699000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46604000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39763000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	163119000	usd
CY2023Q4	arwr	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent	0	usd
CY2023Q4	arwr	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent	1055000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	162064000	usd
CY2022Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	usd
CY2023Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1275000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1700000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1700000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1700000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1700000	usd
CY2023Q4	arwr	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	1762000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9837000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107500000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107500000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107312000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107312000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44907000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45297000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3421000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10563000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	115157000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	104608000	usd
CY2023Q4	us-gaap	Lease Cost LeaseCost	4249000	usd
CY2022Q4	us-gaap	Lease Cost LeaseCost	2812000	usd
CY2023Q4	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2022Q4	us-gaap	Short Term Lease Cost ShortTermLeaseCost	100000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	9044000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	15356000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	15696000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	14869000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	13511000	usd
CY2023Q4	arwr	Lessee Operating Lease Liability Payments Due Year Five And After Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive	128356000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	196832000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	78254000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	118578000	usd
CY2023Q4	arwr	Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities	3099000	usd
CY2022Q4	arwr	Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities	0	usd
CY2023Q4	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	64000	usd
CY2022Q4	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	2080000	usd
CY2022Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	1331000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P13Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5774487	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2200195	shares
CY2023Q4	arwr	Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding	6784893	shares
CY2023Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17685000	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19389000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.68
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	29457	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	61.11
CY2023Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	33825	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.30
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2200195	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.46
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	31862157	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2118298	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	21.72
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M24D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	31840866	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-132864000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-41325000	usd
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107415000	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106039000	shares
CY2023Q4	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2022Q4	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107415000	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106039000	shares
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.24
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.24
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2023Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3544000	shares
CY2022Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3327000	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
arwr-20231231_cal.xml	Edgar Link	unprocessable
arwr-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001628280-24-003492-index-headers.html	Edgar Link	pending
0001628280-24-003492-index.html	Edgar Link	pending
0001628280-24-003492.txt	Edgar Link	pending
0001628280-24-003492-xbrl.zip	Edgar Link	pending
arwr-20231231.htm	Edgar Link	pending
arwr-20231231.xsd	Edgar Link	pending
arwr-20231231xex311.htm	Edgar Link	pending
arwr-20231231xex311001.jpg	Edgar Link	pending
arwr-20231231xex312.htm	Edgar Link	pending
arwr-20231231xex312001.jpg	Edgar Link	pending
arwr-20231231xex321.htm	Edgar Link	pending
arwr-20231231xex321001.jpg	Edgar Link	pending
arwr-20231231xex322.htm	Edgar Link	pending
arwr-20231231xex322001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gsk-amendedandrestatedli.htm	Edgar Link	pending
gsk-amendedandrestatedli001.jpg	Edgar Link	pending
gsk-amendedandrestatedli002.jpg	Edgar Link	pending
gsk-amendedandrestatedli003.jpg	Edgar Link	pending
gsk-amendedandrestatedli004.jpg	Edgar Link	pending
gsk-amendedandrestatedli005.jpg	Edgar Link	pending
gsk-amendedandrestatedli006.jpg	Edgar Link	pending
gsk-amendedandrestatedli007.jpg	Edgar Link	pending
gsk-amendedandrestatedli008.jpg	Edgar Link	pending
gsk-amendedandrestatedli009.jpg	Edgar Link	pending
gsk-amendedandrestatedli010.jpg	Edgar Link	pending
gsk-amendedandrestatedli011.jpg	Edgar Link	pending
gsk-amendedandrestatedli012.jpg	Edgar Link	pending
gsk-amendedandrestatedli013.jpg	Edgar Link	pending
gsk-amendedandrestatedli014.jpg	Edgar Link	pending
gsk-amendedandrestatedli015.jpg	Edgar Link	pending
gsk-amendedandrestatedli016.jpg	Edgar Link	pending
arwr-20231231_def.xml	Edgar Link	unprocessable
arwr-20231231_htm.xml	Edgar Link	completed
gsk-amendedandrestatedli017.jpg	Edgar Link	pending
gsk-amendedandrestatedli018.jpg	Edgar Link	pending
gsk-amendedandrestatedli019.jpg	Edgar Link	pending
gsk-amendedandrestatedli020.jpg	Edgar Link	pending
gsk-amendedandrestatedli021.jpg	Edgar Link	pending
gsk-amendedandrestatedli022.jpg	Edgar Link	pending
gsk-amendedandrestatedli023.jpg	Edgar Link	pending
gsk-amendedandrestatedli024.jpg	Edgar Link	pending
gsk-amendedandrestatedli025.jpg	Edgar Link	pending
gsk-amendedandrestatedli026.jpg	Edgar Link	pending
gsk-amendedandrestatedli027.jpg	Edgar Link	pending
gsk-amendedandrestatedli028.jpg	Edgar Link	pending
gsk-amendedandrestatedli029.jpg	Edgar Link	pending
gsk-amendedandrestatedli030.jpg	Edgar Link	pending
gsk-amendedandrestatedli031.jpg	Edgar Link	pending
gsk-amendedandrestatedli032.jpg	Edgar Link	pending
gsk-amendedandrestatedli033.jpg	Edgar Link	pending
gsk-amendedandrestatedli034.jpg	Edgar Link	pending
gsk-amendedandrestatedli035.jpg	Edgar Link	pending
gsk-amendedandrestatedli036.jpg	Edgar Link	pending
gsk-amendedandrestatedli037.jpg	Edgar Link	pending
gsk-amendedandrestatedli038.jpg	Edgar Link	pending
gsk-amendedandrestatedli039.jpg	Edgar Link	pending
gsk-amendedandrestatedli040.jpg	Edgar Link	pending
gsk-amendedandrestatedli041.jpg	Edgar Link	pending
gsk-amendedandrestatedli042.jpg	Edgar Link	pending
gsk-amendedandrestatedli043.jpg	Edgar Link	pending
gsk-amendedandrestatedli044.jpg	Edgar Link	pending
gsk-amendedandrestatedli045.jpg	Edgar Link	pending
gsk-amendedandrestatedli046.jpg	Edgar Link	pending
gsk-amendedandrestatedli047.jpg	Edgar Link	pending
gsk-amendedandrestatedli048.jpg	Edgar Link	pending
gsk-amendedandrestatedli049.jpg	Edgar Link	pending
gsk-amendedandrestatedli050.jpg	Edgar Link	pending
gsk-amendedandrestatedli051.jpg	Edgar Link	pending
gsk-amendedandrestatedli052.jpg	Edgar Link	pending
gsk-amendedandrestatedli053.jpg	Edgar Link	pending
gsk-amendedandrestatedli054.jpg	Edgar Link	pending
gsk-amendedandrestatedli055.jpg	Edgar Link	pending
gsk-amendedandrestatedli056.jpg	Edgar Link	pending
gsk-amendedandrestatedli057.jpg	Edgar Link	pending
gsk-amendedandrestatedli058.jpg	Edgar Link	pending
gsk-amendedandrestatedli059.jpg	Edgar Link	pending
gsk-amendedandrestatedli060.jpg	Edgar Link	pending
gsk-amendedandrestatedli061.jpg	Edgar Link	pending
gsk-amendedandrestatedli062.jpg	Edgar Link	pending
gsk-amendedandrestatedli063.jpg	Edgar Link	pending
gsk-amendedandrestatedli064.jpg	Edgar Link	pending
gsk-amendedandrestatedli065.jpg	Edgar Link	pending
gsk-amendedandrestatedli066.jpg	Edgar Link	pending
gsk-amendedandrestatedli067.jpg	Edgar Link	pending
gsk-amendedandrestatedli068.jpg	Edgar Link	pending
gsk-amendedandrestatedli069.jpg	Edgar Link	pending
gsk-amendedandrestatedli070.jpg	Edgar Link	pending
gsk-amendedandrestatedli071.jpg	Edgar Link	pending
gsk-amendedandrestatedli072.jpg	Edgar Link	pending
gsk-amendedandrestatedli073.jpg	Edgar Link	pending
gsk-amendedandrestatedli074.jpg	Edgar Link	pending
gsk-amendedandrestatedli075.jpg	Edgar Link	pending
gsk-amendedandrestatedli076.jpg	Edgar Link	pending
gsk-amendedandrestatedli077.jpg	Edgar Link	pending
gsk-amendedandrestatedli078.jpg	Edgar Link	pending
gsk-amendedandrestatedli079.jpg	Edgar Link	pending
gsk-amendedandrestatedli080.jpg	Edgar Link	pending
gsk-amendedandrestatedli081.jpg	Edgar Link	pending
gsk-amendedandrestatedli082.jpg	Edgar Link	pending
gsk-amendedandrestatedli083.jpg	Edgar Link	pending
gsk-amendedandrestatedli084.jpg	Edgar Link	pending
gsk-amendedandrestatedli085.jpg	Edgar Link	pending
gsk-amendedandrestatedli086.jpg	Edgar Link	pending
gsk-amendedandrestatedli087.jpg	Edgar Link	pending
gsk-amendedandrestatedli088.jpg	Edgar Link	pending
gsk-amendedandrestatedli089.jpg	Edgar Link	pending
gsk-amendedandrestatedli090.jpg	Edgar Link	pending
gsk-amendedandrestatedli091.jpg	Edgar Link	pending
gsk-amendedandrestatedli092.jpg	Edgar Link	pending
gsk-amendedandrestatedli093.jpg	Edgar Link	pending
gsk-amendedandrestatedli094.jpg	Edgar Link	pending
gsk-amendedandrestatedli095.jpg	Edgar Link	pending
gsk-amendedandrestatedli096.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
arwr-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

2024 Q1 Form 10-Q Financial Statement

#000162828024003492 Filed on February 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARWR ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

2024 Q1 Form 10-Q Financial Statement

#000162828024003492 Filed on February 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr